abstract: Our study compared the effect of high-dose @entity2 with the pure alpha-agonist @entity5 on regional @entity1 ( @entity1 ), myocardial @entity0 delivery (MDO2), myocardial @entity0 consumption (MVO2), and defibrillation rates during CPR. Fifteen @entity3 weighing more than 15 kg were instrumented for measurement of regional @entity1 using radiolabeled tracer microspheres. Measurements of regional @entity1 , MDO2, and MVO2 were made during normal sinus rhythm. @entity4 was induced and persisted for ten minutes. CPR was begun using a pneumatic compression device. Regional @entity1 , MDO2, and MVO2 were measured during CPR. Following three minutes of CPR, animals (N = 15) were allocated to one of three groups (n = 5): Group 1, @entity2 0.2 mg/kg; Group 2, @entity5 0.1 mg/kg; or Group 3, @entity5 1.0 mg/kg. Measurements of regional @entity1 , MDO2, and MVO2 were repeated after drug administration. Extraction ratios, defined as MVO2/MDO2, were calculated during normal sinus rhythm, CPR, and after drug administration. Defibrillation was attempted 3 1/2 minutes after drug administration. There was no significant difference in @entity1 , MDO2, MVO2, and extraction ratio during normal sinus rhythm and CPR for any of the groups. Total @entity1 following drug administration was 67.2 +/- 49.4 mL/min/100 g for the group receiving @entity2 0.2 mg/kg; 7.0 +/- 7.1 mL/min/100 g for the group receiving @entity5 0.1 mg/kg; and 36.7 +/- 21.1 mL/min/100 g for the group receiving @entity5 1.0 mg/kg.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Myocardial @entity0 delivery/consumption during cardiopulmonary resuscitation: a comparison of @entity2 and XXXX .

answer: @entity5


abstract: Our study compared the effect of high-dose @entity2 with the pure alpha-agonist @entity5 on regional @entity1 ( @entity1 ), myocardial @entity0 delivery (MDO2), myocardial @entity0 consumption (MVO2), and defibrillation rates during CPR. Fifteen @entity3 weighing more than 15 kg were instrumented for measurement of regional @entity1 using radiolabeled tracer microspheres. Measurements of regional @entity1 , MDO2, and MVO2 were made during normal sinus rhythm. @entity4 was induced and persisted for ten minutes. CPR was begun using a pneumatic compression device. Regional @entity1 , MDO2, and MVO2 were measured during CPR. Following three minutes of CPR, animals (N = 15) were allocated to one of three groups (n = 5): Group 1, @entity2 0.2 mg/kg; Group 2, @entity5 0.1 mg/kg; or Group 3, @entity5 1.0 mg/kg. Measurements of regional @entity1 , MDO2, and MVO2 were repeated after drug administration. Extraction ratios, defined as MVO2/MDO2, were calculated during normal sinus rhythm, CPR, and after drug administration. Defibrillation was attempted 3 1/2 minutes after drug administration. There was no significant difference in @entity1 , MDO2, MVO2, and extraction ratio during normal sinus rhythm and CPR for any of the groups. Total @entity1 following drug administration was 67.2 +/- 49.4 mL/min/100 g for the group receiving @entity2 0.2 mg/kg; 7.0 +/- 7.1 mL/min/100 g for the group receiving @entity5 0.1 mg/kg; and 36.7 +/- 21.1 mL/min/100 g for the group receiving @entity5 1.0 mg/kg.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Myocardial XXXX delivery/consumption during cardiopulmonary resuscitation: a comparison of @entity2 and @entity5 .

answer: @entity0


abstract: Our study compared the effect of high-dose @entity2 with the pure alpha-agonist @entity5 on regional @entity1 ( @entity1 ), myocardial @entity0 delivery (MDO2), myocardial @entity0 consumption (MVO2), and defibrillation rates during CPR. Fifteen @entity3 weighing more than 15 kg were instrumented for measurement of regional @entity1 using radiolabeled tracer microspheres. Measurements of regional @entity1 , MDO2, and MVO2 were made during normal sinus rhythm. @entity4 was induced and persisted for ten minutes. CPR was begun using a pneumatic compression device. Regional @entity1 , MDO2, and MVO2 were measured during CPR. Following three minutes of CPR, animals (N = 15) were allocated to one of three groups (n = 5): Group 1, @entity2 0.2 mg/kg; Group 2, @entity5 0.1 mg/kg; or Group 3, @entity5 1.0 mg/kg. Measurements of regional @entity1 , MDO2, and MVO2 were repeated after drug administration. Extraction ratios, defined as MVO2/MDO2, were calculated during normal sinus rhythm, CPR, and after drug administration. Defibrillation was attempted 3 1/2 minutes after drug administration. There was no significant difference in @entity1 , MDO2, MVO2, and extraction ratio during normal sinus rhythm and CPR for any of the groups. Total @entity1 following drug administration was 67.2 +/- 49.4 mL/min/100 g for the group receiving @entity2 0.2 mg/kg; 7.0 +/- 7.1 mL/min/100 g for the group receiving @entity5 0.1 mg/kg; and 36.7 +/- 21.1 mL/min/100 g for the group receiving @entity5 1.0 mg/kg.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Myocardial @entity0 delivery/consumption during cardiopulmonary resuscitation: a comparison of XXXX and @entity5 .

answer: @entity2


abstract: Twenty-eight abscessed livers were collected from feedlot @entity2 at an abattoir; specimens were obtained from 49 abscesses for bacteriologic culture and for histologic examination. Cultural procedures included techniques to enumerate and isolate facultative and obligate anaerobic bacteria. Anaerobic bacteria were isolated from all 49 abscesses, whereas facultative bacteria were isolated from only 22. Mean bacterial counts for anaerobic and facultative bacteria were 3 X 10(8) and 8 X 10(8) bacteria/g of purulent material, respectively. Fusobacterium necrophorum, the only anaerobe isolated, was detected in 100% of the abscesses. Fusobacterium necrophorum biotype A was isolated from 57% of the abscesses (in pure culture from 75%), and F necrophorum biotype B was isolated from 47% of the abscesses (from 96% with @entity3 ). @entity4 was the predominant facultative bacterium isolated. Histologic changes in abscesses were qualitatively similar; abscesses were pyogranulomatous, with a @entity0 center surrounded by zones of inflammatory tissue. However, the severity of lesions varied, depending on the F necrophorum biotype involved. Portal triad @entity1 and bile-duct proliferation were most severe in biotype A and mixed biotype B infections and less severe in abscesses from which biotype B was isolated in pure culture.

title: Bacteriologic and histologic studies of hepatic abscesses in XXXX .

answer: @entity2


abstract: BACKGROUND AND PURPOSE OF THE STUDY: the role of cortical mastoidectomy in the surgical treatment of @entity4 media has remained controversial especially when there is no evidence of @entity3 . Though literature is replete with studies for and against the requirement of mastoidectomy, there is a paucity of prospective studies in this regard. A randomized controlled trial was conducted to assess the impact of mastoidectomy in the management of @entity1 media. METHODS: 62 @entity0 with uncomplicated @entity1 media were randomly allotted to two groups of 31 each. @entity0 in group A underwent tympanoplasty with mastoidectomy and group B underwent tympanoplasty without mastoidectomy. All the @entity0 were followed up for a minimum of three months and results were assessed in terms of graft uptake, hearing improvement and need for repeat procedure. RESULTS: no significant difference in outcome was observed between the two groups in all parameters compared. The residual air-bone gap was 12.55    12.98 in group A and 12.71    11.54 in group B. Graft uptake rate was 93.55% in group A and 96.775% in group B. 2 @entity0 in group A and one @entity0 in group B underwent repeat procedures. CONCLUSIONS: there is little evidence in favour of cortical mastoidectomy in surgery of @entity2 .

title: Cortical mastoidectomy in surgery of XXXX . Are we overdoing it?

answer: @entity2


abstract: A 13-year follow-up study was performed in 301 @entity0 with @entity8 ( @entity8 ). Of these @entity0 , 223 cases, 78 @entity0 (average age 59.3 years) and 145 @entity0 (average age 60.4 years), survived. Seventy-eight cases including 38 @entity0 (mean age of @entity1 72.5 years) and 40 @entity0 (mean age of @entity1 64.8 years) died. @entity8 consisted of 51% mitral @entity2 , 40% combined @entity2 and 9% aortic @entity2 . The mean mortality for all @entity0 with @entity8 was 25.9%. Seventy percent of the @entity1 were due to severe, @entity3 , @entity4 . @entity5 was observed in 50% of the @entity0 . @entity6 occurred frequently in @entity0 with @entity7 ( @entity7 ), mitral stenoregurgitation (MSR) and @entity2 ( @entity2 ), which were associated with @entity5 . However, @entity6 were rarely found in cases with MSR, @entity2 and @entity2 with sinus rhythm. The mortality of cardiac surgery was low, 13.3%.

title: A 13-year follow-up study of XXXX .

answer: @entity2


abstract: The time courses of changes in @entity3 (PA) content, isometric twitch tension, and half-relaxation time (1/2 RT) were studied in @entity1 tibialis anterior muscle following chronic 10 Hz nerve stimulation of 1-21 days. Up to 5 days stimulation had no effect on PA content, but it induced a slight (10-15%) increase in the 1/2 RT. This change occurred together with the previously observed 50% decrease in @entity2 -uptake by the SR (Leberer et al. 1987). While prolonged stimulation produced no further decrease in the @entity2 -uptake by the SR, PA content declined after 5 days of stimulation. The reduction in PA content was accompanied by a progressive lengthening of the 1/2 RT. However, the increase in 1/2 RT was particularly pronounced after PA had fallen below 50% of its normal value. A 90% reduction in PA coincided with a 60% increase in the 1/2 RT. By this time the staircase phenomenon, normally observed in fast-twitch muscle, was completely abolished. Although the changes in PA content and 1/2 RT were not linearly related, these results suggest that PA plays an important role in the relaxation process of @entity0 fast-twitch muscle.

title: Relationship between @entity3 content and the speed of relaxation in chronically stimulated XXXX fast-twitch muscle.

answer: @entity1


abstract: The time courses of changes in @entity3 (PA) content, isometric twitch tension, and half-relaxation time (1/2 RT) were studied in @entity1 tibialis anterior muscle following chronic 10 Hz nerve stimulation of 1-21 days. Up to 5 days stimulation had no effect on PA content, but it induced a slight (10-15%) increase in the 1/2 RT. This change occurred together with the previously observed 50% decrease in @entity2 -uptake by the SR (Leberer et al. 1987). While prolonged stimulation produced no further decrease in the @entity2 -uptake by the SR, PA content declined after 5 days of stimulation. The reduction in PA content was accompanied by a progressive lengthening of the 1/2 RT. However, the increase in 1/2 RT was particularly pronounced after PA had fallen below 50% of its normal value. A 90% reduction in PA coincided with a 60% increase in the 1/2 RT. By this time the staircase phenomenon, normally observed in fast-twitch muscle, was completely abolished. Although the changes in PA content and 1/2 RT were not linearly related, these results suggest that PA plays an important role in the relaxation process of @entity0 fast-twitch muscle.

title: Relationship between XXXX content and the speed of relaxation in chronically stimulated @entity1 fast-twitch muscle.

answer: @entity3


abstract: @entity3 ( @entity3 ) evoked by electrical stimulation of the cholinergic-sympathetic system at different levels were recorded in the forepaws of anaesthetized @entity2 and used as a measure of sudomotor activity. After pretreatment with @entity7 (0.25 mg/kg i.v.) to block alpha 2-adrenoceptors, unilateral electrical stimulation of the hypothalamus (square wave pulses 1 ms duration, 16 Hz, 2 s train length at intervals of 1 min) induced @entity3 in both forepaws. Injection of the inhibitor of neuronal @entity5 reuptake, @entity8 (1 mg/kg i.v.), facilitated the @entity3 in both forepaws, even though access of the drug to the sweat glands was prevented by application of a tourniquet to one paw. The facilitation was abolished by injection of the specific alpha 1-adrenoceptor antagonist, @entity6 (0.5 mg/kg i.v.). An equal enhancement of this effect by @entity8 (1 mg/kg i.v.) and its abolition by @entity6 (0.5 mg/kg i.v.) was obtained in @entity2 with the brain stem transected at the level of the medulla oblongata and electrical stimulation of the spinal cord at C1. @entity3 evoked in the right forepaw by preganglionic electrical stimulation of the right stellate ganglion were inhibited by @entity8 (1 mg/kg i.v.). From these and previous results it is concluded that inhibition of neuronal reuptake of @entity4 results in facilitation of activity in sudomotor efferents. This effect is mediated by spinal alpha 1-adrenoceptors and provides an explanation of the occasional occurrence of excessive sweating in @entity1 @entity0 treated with tricyclic antidepressants.

title: Spinal facilitation in cholinergic-sympathetic efferents by XXXX .

answer: @entity8


abstract: Detection of an intraventricular or intratumoral fat-fluid level on the plain craniograms has been known as a characteristic sign indicating the presence of intracranial @entity0 . On CT scans, however, only thirteen cases have been previously reported to be found an intraventricular and/or subarachnoid free fat associated with @entity0 . We reported a case of @entity5 with intraventricular free-fat seen on CT scans. A nine-year-old male with precocious puberty was admitted to our hospital complaining a moderate @entity1 . Neurological examinations were normal without signs of @entity2 . The serum and CSF titer of HCG were raised markedly. The laboratory data of the CSF were normal and there were no pathological cells in the CSF. The CT scans revealed a large heterogeneous mass containing multiple areas of negative density in the pineal region. There were negative density droplets in the bilateral frontal horn on the same CT scans indicating a presence of free fats. At surgery, an yellowish oily material was drained from the @entity0 , but there was no sign of @entity4 over the cortical surface of the occipital lobe. An intraventricular free fat on CT scan have been reported in fourteen cases including ours following the first case described by Fawcitt in 1976. Although most of the cases presented @entity1 , only two cases was diagnosed clinically as @entity4 . Pathological changes indicating @entity4 , however, were noted in five cases, all of them presenting @entity3 attacks.

title: [A case of XXXX with intraventricular free fat seen in CT scan].

answer: @entity5


abstract: We retrospectively reviewed the charts of 55 @entity0 with @entity4 treated from 1980 to 1983 at the Cleveland Clinic Foundation. The @entity0 were treated by placement of a 10F to 16F soft latex mushroom catheter into the abscess cavity under local anesthesia as an office procedure. The end of the catheter was shortened to leave 2 to 3 cm exiting the skin, and a bandage was applied. No sutures or irrigations were used, and the drains were removed an average of 12 days after placement. Antibiotics were not given. The @entity0 ranged in age from 17 to 76 years (mean, 40 years) and 36% were female. Four @entity0 had @entity1 , and eight had a history of @entity2 . Nine @entity0 had been treated previously for anorectal abscesses. There were no complications. Adequate follow-up was obtainable in 31 @entity0 (ten to 63 months; mean, 30 months). Eight of them (26%) were subsequently treated for @entity3 found after resolution of the abscess, and an additional eight (26%) had a second abscess form during the follow-up period. The average time to this recurrence was 20 months. Catheter drainage of @entity4 in selected cases resulted in healing with low morbidity and significant cost savings.

title: Catheter drainage of XXXX .

answer: @entity4


abstract: A series of 4992 intracranial procedures performed over an 11-year period was evaluated for the occurrence of @entity2 . Forty @entity0 (0.8%) experienced @entity2 . Twenty-four @entity5 were intracerebral (60%), 11 were epidural (28%), 3 were subdural (7.5%), and 2 were intrasellar (5.0%). @entity6 in 33 @entity0 occurred at the operative site, and 7 occurred remote from the operative site. @entity1 was the reason for operation in 56% of the @entity0 developing a clot, and @entity7 was the most common @entity1 associated with this complication. The use of the sitting position was not associated with an increased incidence of @entity2 . @entity4 and @entity3 seemed to be potential precipitating factors. @entity2 was recognized within 12 hours of operation in 35% of the @entity0 . An altered level of consciousness was the most frequent clinical finding, present in all @entity0 . There was no clear relationship between the time of recognition and the final clinical outcome. Parenchymal clots carried the worst prognosis, accounting for 8 of the 11 deaths and all 7 @entity0 with poor neurological outcome.

title: XXXX : a survey of 4992 intracranial procedures.

answer: @entity2


abstract: BACKGROUND: @entity10 is associated with @entity12 in @entity0 or @entity9 and @entity4 in adults. The virus is relatively conserved and @entity3 identity is expected in viruses that are epidemiologically related. Here, we describe the first cluster of @entity11 among hospital staff documented in Taiwan. METHODS: Active surveillance was conducted in coronary care units (CCUs) at a 2200-bed teaching hospital for 1 month in 2007. A case defined clinically as occurring in a @entity0 or staff in CCUs with new onset of @entity1 or @entity7 . Serum was tested for @entity10 IgM and IgG by immunoblotting and DNA by nested polymerase chain reaction. When @entity5 was detected, @entity3 sequences were analyzed and compared with those of two clinical isolates. The attack rate was defined as the cumulative incidence of @entity6 in CCU staff and @entity0 during the study period. RESULTS: Among 57 staff and 15 @entity0 , five nurses met the clinical case definition. Three had @entity6 as demonstrated by viral DNA and IgM. The attack rate was 5.3% for the staff and zero for @entity0 . Seroprevalence rate was lower in staff than in @entity0 (26.3%vs. 53.3%). The isolates collected from three cases were highly similar to a community isolate, and they varied with each other by 2-6 @entity8 . The isolate collected from a nurse was identical to that from her friend 3 weeks apart and was concordant with mutual transmission. A sequence with 45 @entity3 variations was identified from a staff member with @entity2 who was negative for IgM and had only weak IgG anti-VP1 reaction with immunoblotting. We did not find any @entity0 as the source of @entity2 . CONCLUSION: We identified a cluster of @entity11 that was caused by three circulating strains which did not support the hypothesis of transmission of a single strain in CCUs.

title: Cluster of XXXX among hospital staff working in coronary care units.

answer: @entity11


abstract: BACKGROUND: Platycodon grandiflorum is a traditional Asian medicine that is used to treat @entity5 . OBJECTIVE: to investigate the effects of P grandiflorum in vivo in an animal model of @entity6 ( @entity6 ), with particular emphasis on its effects on @entity11 and @entity3 immune responses. METHODS: we established a model of @entity6 -like @entity4 in NC/Nga @entity0 . After oral administration of P grandiflorum, we measured cytokine and immunoglobulin profiles along with histologic examination of skin. RESULTS: P grandiflorum was nontoxic in a @entity10 -induced model of @entity6 -like @entity4 in NC/Nga @entity0 . @entity6 symptoms in @entity4 improved after oral administration of P grandiflorum. IgE secretion was significantly downregulated in P grandiflorum-treated animals, accompanied by decreased levels of @entity1 and @entity7 and increased serum levels of @entity9 and @entity8 . In isolated splenocytes, the production of the @entity11 cytokines @entity9 and interferon-y was upregulated by P grandiflorum, whereas the levels of the @entity3 cytokines @entity1 and @entity2 were downregulated in a @entity0 model of @entity6 -like @entity4 . CONCLUSIONS: these results suggest that P grandiflorum inhibits the development of @entity6 -like @entity4 in NC/Nga @entity0 by suppressing the @entity3 cell response and increasing the @entity11 cell responses. Our results indicate that P grandiflorum is safe and effective as a natural herbal medicine for the treatment of @entity6 -like @entity4 .

title: Inhibitory effect of Platycodon grandiflorum on @entity11 and @entity3 immune responses in a @entity0 model of @entity10 -induced XXXX .

answer: @entity4


abstract: BACKGROUND: Platycodon grandiflorum is a traditional Asian medicine that is used to treat @entity5 . OBJECTIVE: to investigate the effects of P grandiflorum in vivo in an animal model of @entity6 ( @entity6 ), with particular emphasis on its effects on @entity11 and @entity3 immune responses. METHODS: we established a model of @entity6 -like @entity4 in NC/Nga @entity0 . After oral administration of P grandiflorum, we measured cytokine and immunoglobulin profiles along with histologic examination of skin. RESULTS: P grandiflorum was nontoxic in a @entity10 -induced model of @entity6 -like @entity4 in NC/Nga @entity0 . @entity6 symptoms in @entity4 improved after oral administration of P grandiflorum. IgE secretion was significantly downregulated in P grandiflorum-treated animals, accompanied by decreased levels of @entity1 and @entity7 and increased serum levels of @entity9 and @entity8 . In isolated splenocytes, the production of the @entity11 cytokines @entity9 and interferon-y was upregulated by P grandiflorum, whereas the levels of the @entity3 cytokines @entity1 and @entity2 were downregulated in a @entity0 model of @entity6 -like @entity4 . CONCLUSIONS: these results suggest that P grandiflorum inhibits the development of @entity6 -like @entity4 in NC/Nga @entity0 by suppressing the @entity3 cell response and increasing the @entity11 cell responses. Our results indicate that P grandiflorum is safe and effective as a natural herbal medicine for the treatment of @entity6 -like @entity4 .

title: Inhibitory effect of Platycodon grandiflorum on XXXX and @entity3 immune responses in a @entity0 model of @entity10 -induced @entity4 .

answer: @entity11


abstract: BACKGROUND: Platycodon grandiflorum is a traditional Asian medicine that is used to treat @entity5 . OBJECTIVE: to investigate the effects of P grandiflorum in vivo in an animal model of @entity6 ( @entity6 ), with particular emphasis on its effects on @entity11 and @entity3 immune responses. METHODS: we established a model of @entity6 -like @entity4 in NC/Nga @entity0 . After oral administration of P grandiflorum, we measured cytokine and immunoglobulin profiles along with histologic examination of skin. RESULTS: P grandiflorum was nontoxic in a @entity10 -induced model of @entity6 -like @entity4 in NC/Nga @entity0 . @entity6 symptoms in @entity4 improved after oral administration of P grandiflorum. IgE secretion was significantly downregulated in P grandiflorum-treated animals, accompanied by decreased levels of @entity1 and @entity7 and increased serum levels of @entity9 and @entity8 . In isolated splenocytes, the production of the @entity11 cytokines @entity9 and interferon-y was upregulated by P grandiflorum, whereas the levels of the @entity3 cytokines @entity1 and @entity2 were downregulated in a @entity0 model of @entity6 -like @entity4 . CONCLUSIONS: these results suggest that P grandiflorum inhibits the development of @entity6 -like @entity4 in NC/Nga @entity0 by suppressing the @entity3 cell response and increasing the @entity11 cell responses. Our results indicate that P grandiflorum is safe and effective as a natural herbal medicine for the treatment of @entity6 -like @entity4 .

title: Inhibitory effect of Platycodon grandiflorum on @entity11 and @entity3 immune responses in a @entity0 model of XXXX -induced @entity4 .

answer: @entity10


abstract: BACKGROUND: Platycodon grandiflorum is a traditional Asian medicine that is used to treat @entity5 . OBJECTIVE: to investigate the effects of P grandiflorum in vivo in an animal model of @entity6 ( @entity6 ), with particular emphasis on its effects on @entity11 and @entity3 immune responses. METHODS: we established a model of @entity6 -like @entity4 in NC/Nga @entity0 . After oral administration of P grandiflorum, we measured cytokine and immunoglobulin profiles along with histologic examination of skin. RESULTS: P grandiflorum was nontoxic in a @entity10 -induced model of @entity6 -like @entity4 in NC/Nga @entity0 . @entity6 symptoms in @entity4 improved after oral administration of P grandiflorum. IgE secretion was significantly downregulated in P grandiflorum-treated animals, accompanied by decreased levels of @entity1 and @entity7 and increased serum levels of @entity9 and @entity8 . In isolated splenocytes, the production of the @entity11 cytokines @entity9 and interferon-y was upregulated by P grandiflorum, whereas the levels of the @entity3 cytokines @entity1 and @entity2 were downregulated in a @entity0 model of @entity6 -like @entity4 . CONCLUSIONS: these results suggest that P grandiflorum inhibits the development of @entity6 -like @entity4 in NC/Nga @entity0 by suppressing the @entity3 cell response and increasing the @entity11 cell responses. Our results indicate that P grandiflorum is safe and effective as a natural herbal medicine for the treatment of @entity6 -like @entity4 .

title: Inhibitory effect of Platycodon grandiflorum on @entity11 and XXXX immune responses in a @entity0 model of @entity10 -induced @entity4 .

answer: @entity3


abstract: BACKGROUND: Platycodon grandiflorum is a traditional Asian medicine that is used to treat @entity5 . OBJECTIVE: to investigate the effects of P grandiflorum in vivo in an animal model of @entity6 ( @entity6 ), with particular emphasis on its effects on @entity11 and @entity3 immune responses. METHODS: we established a model of @entity6 -like @entity4 in NC/Nga @entity0 . After oral administration of P grandiflorum, we measured cytokine and immunoglobulin profiles along with histologic examination of skin. RESULTS: P grandiflorum was nontoxic in a @entity10 -induced model of @entity6 -like @entity4 in NC/Nga @entity0 . @entity6 symptoms in @entity4 improved after oral administration of P grandiflorum. IgE secretion was significantly downregulated in P grandiflorum-treated animals, accompanied by decreased levels of @entity1 and @entity7 and increased serum levels of @entity9 and @entity8 . In isolated splenocytes, the production of the @entity11 cytokines @entity9 and interferon-y was upregulated by P grandiflorum, whereas the levels of the @entity3 cytokines @entity1 and @entity2 were downregulated in a @entity0 model of @entity6 -like @entity4 . CONCLUSIONS: these results suggest that P grandiflorum inhibits the development of @entity6 -like @entity4 in NC/Nga @entity0 by suppressing the @entity3 cell response and increasing the @entity11 cell responses. Our results indicate that P grandiflorum is safe and effective as a natural herbal medicine for the treatment of @entity6 -like @entity4 .

title: Inhibitory effect of Platycodon grandiflorum on @entity11 and @entity3 immune responses in a XXXX model of @entity10 -induced @entity4 .

answer: @entity0


abstract: OBJECTIVE: To investigate whether temporarily withholding FSH and adding @entity2 could improve follicular response during a microdose  flare protocol in @entity0 with slow follicular growth or asynchronous follicular development. DESIGN: Observational pilot study. SETTING: University-affiliated private fertility center. @entity0 (S): Twenty-six @entity0 aged 34-47  years with poor response to stimulation or a previous cancelled IVF cycle and with slow or asynchronous follicular growth during a microdose flare cycle. INTERVENTION(S): For 13 @entity0 , after initiation of ovarian stimulation using the microdose flare protocol, gonadotropin administration was interrupted and transdermal @entity1 gel was added for several days (4.4    1.2  d) starting after cycle day 7 (mean cycle day 10    2.6). MAIN OUTCOME MEASURE(S): FSH, E2, follicular growth, and total number of mature oocytes retrieved were determined for all of the @entity0 . Cycle cancellation rate as well as pregnancy rate following embryo transfer were also documented when applicable. RESULT(S): FSH levels declined (25.2    6.5 to 6.8    3.2 IU/L), E2 levels increased (896    687 to 2,163    1,667 pmol/L), and follicular growth improved significantly during gonadotropin interruption and were tracked for 2  days during this time frame. The average number of oocytes retrieved was 5.3    2.6, and the ratio of mature to total oocytes was 4:5. Four of the 13 @entity0 in the interruption group conceived following frozen embryo transfer, whereas none in the control group did. CONCLUSION(S): The @entity2 -interrupted FSH protocol may improve follicular response to gonadotropins in cycles that might otherwise be cancelled.

title: Microdose flare protocol with interrupted follicle stimulating hormone and added XXXX for  poor responders-an observational pilot study.

answer: @entity2


abstract: OBJECTIVE: To systematically review previous studies and to evaluate the feasibility and safety of video endoscopic inguinal lymphadenectomy (VEIL) in @entity1 . METHODS: We conducted a comprehensive review of studies published through September 2014 to retrieve all relevant articles. The PubMed, EMBASE, Web of Science, Cochrane Library, Wan Fang Data and Chinese National Knowledge Infrastructure databases were systematically searched for all relevant studies published in English or Chinese through September 2014. Data were abstracted independently by two reviewers, and any differences were resolved by consensus. RESULTS: A total of 9 studies containing 249 VEIL procedures involving 138 @entity0 were reviewed. Of the 249 VEIL procedures, only 1 (0.4%) was converted to an open procedure for suturing because of @entity2 . The range of operative time was 62 to 110 minutes, and the range of estimated @entity3 was 5.5 to 22 ml. The range of the number of harvested lymph nodes was 7.3 to 16. The length of hospital stay varied from 7 to 13.6 days across reports. The incidence of @entity4 was 19.7% (27/138), and the recurrence rate was 4.3% (3/70) within 3 to 41 months of follow-up. One or more short-term complications were documented in 18 of 138 (13.0%) @entity0 . Complications after VEIL were observed in 14 (10.13%) @entity0 and in 15 (6.0%) of the VEIL cases, including major lymphocyst formation in 9 (3.6%), lymphorrhea in 2 (0.8%), @entity5 without wound breakdown in 3 (1.2%) and @entity6 in 1 (0.4%). CONCLUSIONS: VEIL appears to be a feasible procedure in the management of @entity1 . There may be potential benefits that result in lower morbidity compared to traditional methods, but this has yet to be objectively proven.

title: Feasibility and Safety of Video Endoscopic Inguinal Lymphadenectomy in XXXX : A Systematic Review.

answer: @entity1


abstract: The effects of various i.v. doses of @entity1 (Voltaren, 1.5, 3, 6 and 9 mg/kg) were evaluated by measuring the vocalization threshold in response to paw pressure in normal and in Freund's adjuvant-induced arthritic @entity0 . An electrophysiological study performed in parallel in arthritic @entity0 considered the effects of 6 mg/kg i.v. @entity1 on ventrobasal thalamic neuronal responses driven by mild stimulation of an inflamed joint. In normal @entity0 , 6 and 9 mg/kg i.v. @entity1 raised vocalization thresholds significantly (maximum vocalization thresholds were respectively 135.67 +/- 3.30% and 157.41 +/- 4.62% of the preinjection control at 30 min, n = 9 in each group), while no effect was observed with 3 mg/kg. In arthritic @entity0 , i.v. doses of 3, 6 and 9 mg/kg @entity1 induced a clear analgesic effect (maximum vocalization thresholds were respectively 172.22 +/- 4.26, 201.78 +/- 4.76, 222.33 +/- 5.10% of the control at 25 min, n = 9 in each group), whereas a dose of 1.5 mg/kg i.v. did not raise the threshold. In arthritic @entity0 , the VB neuronal responses were depressed by about 50% 20 min after an injection of 6 mg/kg i.v. @entity1 . These results clearly establish that @entity1 produces a dose-dependent analgesic effect, which is more potent in arthritic than in normal @entity0 .

title: Behavioural and electrophysiological evidence for an analgesic effect of a non-steroidal anti-inflammatory agent, XXXX .

answer: @entity1


abstract: BACKGROUND/PURPOSE: There have been many reported cases of @entity9 @entity8 in Europe and the United States, but only a few from Taiwan. The present study was undertaken to analyze the clinical characteristics of @entity0 with @entity9 @entity8 in Taiwan. METHODS: @entity0 with culture-confirmed @entity9 @entity8 were identified at Chang Gung Memorial Hospital between January 2001 and December 2008. The clinical features and outcomes of the @entity0 and the antimicrobial susceptibilities of the clinical isolates were analyzed. RESULTS: Forty-three @entity0 , including two newborn babies (4.7%) and 41 adults (95.3%), with at least one episode of Listeria @entity8 were identified. Forty-two (97.7%) of these @entity0 had underlying diseases. Thirty-three @entity0 (76.7%) had @entity3 , 14 (32.6%) had experienced @entity5 , and 11 (25.6%) had reported changes in consciousness. Twelve @entity0 died within 14 days of @entity4 , corresponding to a case-fatality rate of 27.9%. All the clinical isolates tested were susceptible to @entity6 , @entity2 and @entity7 . CONCLUSION: Most cases of @entity9 @entity4 occurred in adults with underlying diseases, especially @entity1 , and only two cases of neonatal @entity9 @entity8 were identified over the 8-year period. @entity2 , @entity6 and @entity7 could be used for the treatment of @entity9 @entity8 , with the case-fatality rate lower for @entity0 who received appropriate treatment.

title: Epidemiology and clinical characteristics of @entity9 XXXX in a Taiwanese medical center.

answer: @entity8


abstract: BACKGROUND/PURPOSE: There have been many reported cases of @entity9 @entity8 in Europe and the United States, but only a few from Taiwan. The present study was undertaken to analyze the clinical characteristics of @entity0 with @entity9 @entity8 in Taiwan. METHODS: @entity0 with culture-confirmed @entity9 @entity8 were identified at Chang Gung Memorial Hospital between January 2001 and December 2008. The clinical features and outcomes of the @entity0 and the antimicrobial susceptibilities of the clinical isolates were analyzed. RESULTS: Forty-three @entity0 , including two newborn babies (4.7%) and 41 adults (95.3%), with at least one episode of Listeria @entity8 were identified. Forty-two (97.7%) of these @entity0 had underlying diseases. Thirty-three @entity0 (76.7%) had @entity3 , 14 (32.6%) had experienced @entity5 , and 11 (25.6%) had reported changes in consciousness. Twelve @entity0 died within 14 days of @entity4 , corresponding to a case-fatality rate of 27.9%. All the clinical isolates tested were susceptible to @entity6 , @entity2 and @entity7 . CONCLUSION: Most cases of @entity9 @entity4 occurred in adults with underlying diseases, especially @entity1 , and only two cases of neonatal @entity9 @entity8 were identified over the 8-year period. @entity2 , @entity6 and @entity7 could be used for the treatment of @entity9 @entity8 , with the case-fatality rate lower for @entity0 who received appropriate treatment.

title: Epidemiology and clinical characteristics of XXXX @entity8 in a Taiwanese medical center.

answer: @entity9


abstract: To assess whether the prophylactic administration of @entity7 , a new @entity2 antagonist, protects the heart against the effects of @entity1 and reperfusion, @entity0 were injected intraperitoneally twice daily for 5 days with 5 mg/kg body weight of this drug. The heart was then isolated and perfused by the Langendorff technique. @entity6 nuclear magnetic resonance spectroscopy was used to monitor myocardial energy metabolism and intracellular pH during control perfusion and 30 min of total @entity1 (37 degrees C), followed by 30 min of reperfusion. Pretreatment with @entity7 altered neither left ventricular developed pressure under normoxic conditions nor the rate and extent of depletion of @entity3 ( @entity3 ) and @entity5 during @entity1 . Intracellular acidification, however, was attenuated. On reperfusion, hearts from @entity7 -pretreated animals recovered significantly better than untreated hearts with respect to replenishment of @entity3 and @entity5 stores, restitution of low levels of intracellular inorganic @entity4 and recovery of left ventricular function and coronary flow. Intracellular pH recovered rapidly to preischemic levels, whereas in untreated hearts a complex intracellular inorganic @entity4 peak indicated the existence of areas of different pH within the myocardium. It is concluded that @entity7 pretreatment protects the heart against some of the deleterious effects of @entity1 and reperfusion. Because this protection occurred in the absence of a negative inotropic effect during normoxia, it cannot be attributed to an energy-sparing effect during @entity1 . Therefore, alternative mechanisms of action are to be considered.

title: Protective effect of pretreatment with the @entity2 antagonist @entity7 on the ischemic-reperfused @entity0 myocardium: a XXXX nuclear magnetic resonance study.

answer: @entity6


abstract: To assess whether the prophylactic administration of @entity7 , a new @entity2 antagonist, protects the heart against the effects of @entity1 and reperfusion, @entity0 were injected intraperitoneally twice daily for 5 days with 5 mg/kg body weight of this drug. The heart was then isolated and perfused by the Langendorff technique. @entity6 nuclear magnetic resonance spectroscopy was used to monitor myocardial energy metabolism and intracellular pH during control perfusion and 30 min of total @entity1 (37 degrees C), followed by 30 min of reperfusion. Pretreatment with @entity7 altered neither left ventricular developed pressure under normoxic conditions nor the rate and extent of depletion of @entity3 ( @entity3 ) and @entity5 during @entity1 . Intracellular acidification, however, was attenuated. On reperfusion, hearts from @entity7 -pretreated animals recovered significantly better than untreated hearts with respect to replenishment of @entity3 and @entity5 stores, restitution of low levels of intracellular inorganic @entity4 and recovery of left ventricular function and coronary flow. Intracellular pH recovered rapidly to preischemic levels, whereas in untreated hearts a complex intracellular inorganic @entity4 peak indicated the existence of areas of different pH within the myocardium. It is concluded that @entity7 pretreatment protects the heart against some of the deleterious effects of @entity1 and reperfusion. Because this protection occurred in the absence of a negative inotropic effect during normoxia, it cannot be attributed to an energy-sparing effect during @entity1 . Therefore, alternative mechanisms of action are to be considered.

title: Protective effect of pretreatment with the @entity2 antagonist XXXX on the ischemic-reperfused @entity0 myocardium: a @entity6 nuclear magnetic resonance study.

answer: @entity7


abstract: To assess whether the prophylactic administration of @entity7 , a new @entity2 antagonist, protects the heart against the effects of @entity1 and reperfusion, @entity0 were injected intraperitoneally twice daily for 5 days with 5 mg/kg body weight of this drug. The heart was then isolated and perfused by the Langendorff technique. @entity6 nuclear magnetic resonance spectroscopy was used to monitor myocardial energy metabolism and intracellular pH during control perfusion and 30 min of total @entity1 (37 degrees C), followed by 30 min of reperfusion. Pretreatment with @entity7 altered neither left ventricular developed pressure under normoxic conditions nor the rate and extent of depletion of @entity3 ( @entity3 ) and @entity5 during @entity1 . Intracellular acidification, however, was attenuated. On reperfusion, hearts from @entity7 -pretreated animals recovered significantly better than untreated hearts with respect to replenishment of @entity3 and @entity5 stores, restitution of low levels of intracellular inorganic @entity4 and recovery of left ventricular function and coronary flow. Intracellular pH recovered rapidly to preischemic levels, whereas in untreated hearts a complex intracellular inorganic @entity4 peak indicated the existence of areas of different pH within the myocardium. It is concluded that @entity7 pretreatment protects the heart against some of the deleterious effects of @entity1 and reperfusion. Because this protection occurred in the absence of a negative inotropic effect during normoxia, it cannot be attributed to an energy-sparing effect during @entity1 . Therefore, alternative mechanisms of action are to be considered.

title: Protective effect of pretreatment with the XXXX antagonist @entity7 on the ischemic-reperfused @entity0 myocardium: a @entity6 nuclear magnetic resonance study.

answer: @entity2


abstract: To assess whether the prophylactic administration of @entity7 , a new @entity2 antagonist, protects the heart against the effects of @entity1 and reperfusion, @entity0 were injected intraperitoneally twice daily for 5 days with 5 mg/kg body weight of this drug. The heart was then isolated and perfused by the Langendorff technique. @entity6 nuclear magnetic resonance spectroscopy was used to monitor myocardial energy metabolism and intracellular pH during control perfusion and 30 min of total @entity1 (37 degrees C), followed by 30 min of reperfusion. Pretreatment with @entity7 altered neither left ventricular developed pressure under normoxic conditions nor the rate and extent of depletion of @entity3 ( @entity3 ) and @entity5 during @entity1 . Intracellular acidification, however, was attenuated. On reperfusion, hearts from @entity7 -pretreated animals recovered significantly better than untreated hearts with respect to replenishment of @entity3 and @entity5 stores, restitution of low levels of intracellular inorganic @entity4 and recovery of left ventricular function and coronary flow. Intracellular pH recovered rapidly to preischemic levels, whereas in untreated hearts a complex intracellular inorganic @entity4 peak indicated the existence of areas of different pH within the myocardium. It is concluded that @entity7 pretreatment protects the heart against some of the deleterious effects of @entity1 and reperfusion. Because this protection occurred in the absence of a negative inotropic effect during normoxia, it cannot be attributed to an energy-sparing effect during @entity1 . Therefore, alternative mechanisms of action are to be considered.

title: Protective effect of pretreatment with the @entity2 antagonist @entity7 on the ischemic-reperfused XXXX myocardium: a @entity6 nuclear magnetic resonance study.

answer: @entity0


abstract: The clinical and pathological features of six @entity0 with so-called "intraventricular @entity3 " are reported. The @entity1 had no predilection for sex, and the @entity0 ' age at diagnosis ranged from 15 to 39 years. The lesions were located in the lateral and/or third ventricles. Total @entity1 was performed in three @entity0 , and the remaining three underwent partial resection. Postoperative irradiation was given to five @entity0 . A follow-up study revealed that five @entity0 were free of recurrent @entity1 at 15 to 227 months after treatment, and one was alive with disease 25 months after surgery. Histologically, all @entity1 were composed of small uniform cells, with perinuclear halos and regular round nuclei. @entity1 cells were sometimes arranged around nucleus-free fibrillary zones. Mitoses were infrequent. Ultrastructurally, neoplastic cells had round nuclei with dispersed heterochromatin and organelle-sparse cytoplasm containing occasional microtubules, 20 to 25 nm in diameter, and scattered dense-core vesicles, 100 to 200 nm in diameter. Cell processes containing dense-core and clear vesicles were frequently present. Thus, these @entity1 should be considered neuronal in origin, and should be classified as " @entity2 ."

title: XXXX : clinicopathological features of six cases.

answer: @entity2


abstract: @entity4 in the doses of 4 or 16 mg/kg failed to affect copulatory behavior of @entity2 -treated castrated male @entity0 . @entity3 10 mg/kg, administered 60 min before behavioral observation, reduced the proportion of animals displaying @entity1 . Doses of 2.5 or 5 mg/kg reduced the latency to the second ejaculation, whereas the few animals still copulating after @entity3 10 mg/kg showed a reduced latency to the first ejaculation. The same doses of @entity3 administered 5 min before behavioral observation produced a dose-dependent reduction of mount, intromission and ejaculation percentages. However, those animals that did copulate showed a normal copulatory behavior. @entity5 ( @entity5 ) infused into the left cerebral ventricle in a dose of 5 micrograms 5 or 60 min before tests had no effect. When the peptide was infused 30 sec after the first intromission, the number of intromissions as well as the latency to ejaculation were reduced. Opioids may facilitate ejaculatory mechanisms, perhaps as a consequence of their rewarding properties. Moreover, in animals treated with @entity5 after the first intromission, the number of intromissions and the latency to ejaculation were similar for the first and second copulatory series, while these parameters were much reduced upon the second ejaculation for control animals. It is possible that liberation of endogenous opioids is the cause of ejaculation-induced facilitation of subsequent @entity1 .

title: Opioids and XXXX in the male @entity0 .

answer: @entity1


abstract: @entity4 in the doses of 4 or 16 mg/kg failed to affect copulatory behavior of @entity2 -treated castrated male @entity0 . @entity3 10 mg/kg, administered 60 min before behavioral observation, reduced the proportion of animals displaying @entity1 . Doses of 2.5 or 5 mg/kg reduced the latency to the second ejaculation, whereas the few animals still copulating after @entity3 10 mg/kg showed a reduced latency to the first ejaculation. The same doses of @entity3 administered 5 min before behavioral observation produced a dose-dependent reduction of mount, intromission and ejaculation percentages. However, those animals that did copulate showed a normal copulatory behavior. @entity5 ( @entity5 ) infused into the left cerebral ventricle in a dose of 5 micrograms 5 or 60 min before tests had no effect. When the peptide was infused 30 sec after the first intromission, the number of intromissions as well as the latency to ejaculation were reduced. Opioids may facilitate ejaculatory mechanisms, perhaps as a consequence of their rewarding properties. Moreover, in animals treated with @entity5 after the first intromission, the number of intromissions and the latency to ejaculation were similar for the first and second copulatory series, while these parameters were much reduced upon the second ejaculation for control animals. It is possible that liberation of endogenous opioids is the cause of ejaculation-induced facilitation of subsequent @entity1 .

title: Opioids and @entity1 in the male XXXX .

answer: @entity0


abstract: UNASSIGNED: Pain-related @entity2 and fear are associated with increased difficulties in attention, increased awareness of @entity3 , @entity1 from @entity3 , and can moderate the effects of attentional coping attempts. Accurately assessing the direct impact of @entity3 -related @entity2 and fear on @entity3 behavior has proved difficult. Studies have demonstrated no or limited influence of @entity3 -related fear and @entity2 on behavior but this may be due to inherent problems with the scales used. Neuroimaging has improved the understanding of neural processes underlying the factors that influence @entity3 perception. This study aimed to establish if a @entity5 ( @entity5 ), largely developed from the Photographs of Daily Activity (PHODA) assessment tool, could help explore how @entity0 living with chronic @entity3 process information about daily activities. Blood oxygenation level dependent (BOLD) functional magnetic resonance imaging (fMRI) was used to compare brain responses in @entity0 with chronic @entity4 (CMSKP) (n = 15) and healthy controls (n = 15). Subjects were asked to imagine how they would feel mentally and physically if asked to perform daily activities illustrated in @entity5 . The results found that a number of regions involved in @entity3 processing saw increased BOLD activation in @entity0 compared with controls when undertaking the task and included the insula, anterior cingulate cortex, thalamus and inferior and superior parietal cortices. Similarly, increased BOLD responses in @entity0 compared to controls in the frontal pole, paracingulate and the supplementary motor cortex may be suggestive of a memory component to the responses The amygdala, orbitofrontal cortex, substantia nigra/ventral tegmentum, putamen, thalamus, pallidum, inferior parietal (supramarginal and angular gyrus) and cingulate cortex were also seen to have greater differences in BOLD signal changes in @entity0 compared with controls and many of these regions are also associated with general phobic responses. Therefore, we suggest that @entity5 is a useful task to explore @entity3 - and movement-related @entity2 and fear in fMRI studies. Regions in the Default Mode Network remained active or were less deactivated during the @entity5 task in @entity0 with CMSKP compared to healthy controls supporting the contention that the DMN is abnormal in @entity0 with CMSKP.

title: A Functional Magnetic Resonance Imaging Study to Investigate the Utility of a Picture Imagination Task in Investigating Neural Responses in @entity0 with XXXX to Daily Physical Activity Photographs.

answer: @entity4


abstract: UNASSIGNED: Pain-related @entity2 and fear are associated with increased difficulties in attention, increased awareness of @entity3 , @entity1 from @entity3 , and can moderate the effects of attentional coping attempts. Accurately assessing the direct impact of @entity3 -related @entity2 and fear on @entity3 behavior has proved difficult. Studies have demonstrated no or limited influence of @entity3 -related fear and @entity2 on behavior but this may be due to inherent problems with the scales used. Neuroimaging has improved the understanding of neural processes underlying the factors that influence @entity3 perception. This study aimed to establish if a @entity5 ( @entity5 ), largely developed from the Photographs of Daily Activity (PHODA) assessment tool, could help explore how @entity0 living with chronic @entity3 process information about daily activities. Blood oxygenation level dependent (BOLD) functional magnetic resonance imaging (fMRI) was used to compare brain responses in @entity0 with chronic @entity4 (CMSKP) (n = 15) and healthy controls (n = 15). Subjects were asked to imagine how they would feel mentally and physically if asked to perform daily activities illustrated in @entity5 . The results found that a number of regions involved in @entity3 processing saw increased BOLD activation in @entity0 compared with controls when undertaking the task and included the insula, anterior cingulate cortex, thalamus and inferior and superior parietal cortices. Similarly, increased BOLD responses in @entity0 compared to controls in the frontal pole, paracingulate and the supplementary motor cortex may be suggestive of a memory component to the responses The amygdala, orbitofrontal cortex, substantia nigra/ventral tegmentum, putamen, thalamus, pallidum, inferior parietal (supramarginal and angular gyrus) and cingulate cortex were also seen to have greater differences in BOLD signal changes in @entity0 compared with controls and many of these regions are also associated with general phobic responses. Therefore, we suggest that @entity5 is a useful task to explore @entity3 - and movement-related @entity2 and fear in fMRI studies. Regions in the Default Mode Network remained active or were less deactivated during the @entity5 task in @entity0 with CMSKP compared to healthy controls supporting the contention that the DMN is abnormal in @entity0 with CMSKP.

title: A Functional Magnetic Resonance Imaging Study to Investigate the Utility of a Picture Imagination Task in Investigating Neural Responses in XXXX with @entity4 to Daily Physical Activity Photographs.

answer: @entity0


abstract: AIMS: Survival after out-of-hospital @entity2 (OHCA) remains disappointingly low. Among @entity0 admitted alive, early prognostication remains challenging. This study aims to establish a stratification score for @entity0 admitted in intensive care unit (ICU) after OHCA, according to their neurological outcome. METHODS AND RESULTS: The CAHP ( @entity2 Hospital Prognosis) score was developed from the @entity1 Expertise Center registry (Paris, France). The primary outcome was poor neurological outcome defined as Cerebral Performance Category 3, 4, or 5 at hospital discharge. Independent prognostic factors were identified using logistic regression analysis and thresholds defined to stratify low-, moderate-, and high-risk groups. The CAHP score was validated in both a prospective and an external data set (Parisian @entity2 Registry). The developmental data set included 819 @entity0 admitted from May 2011 to December 2012. After multivariate analysis, seven variables were independently associated with poor neurological outcome and subsequently included in the CAHP score (age, non-shockable rhythm, time from collapse to basic life support, time from basic life support to return of spontaneous circulation, location of @entity2 , @entity3 dose, and arterial pH). Three risks groups were identified: low risk (score  <=150, 39% of unfavourable outcome), medium risk (score 150-200, 81% of unfavourable outcome) and high-risk group (score >= 200, 100% of unfavourable outcome). The AUC of the CAHP score were 0.93, and the discrimination value in the validation data sets was consistent (respectively, AUC 0.91 and 0.85). CONCLUSION: The CAHP score represents a simple tool for early stratification of @entity0 admitted in ICU after OHCA. A high-risk category of @entity0 with very poor prognosis can be easily identified.

title: The CAHP ( XXXX Hospital Prognosis) score: a tool for risk stratification after out-of-hospital @entity2 .

answer: @entity2


abstract: AIMS: Survival after out-of-hospital @entity2 (OHCA) remains disappointingly low. Among @entity0 admitted alive, early prognostication remains challenging. This study aims to establish a stratification score for @entity0 admitted in intensive care unit (ICU) after OHCA, according to their neurological outcome. METHODS AND RESULTS: The CAHP ( @entity2 Hospital Prognosis) score was developed from the @entity1 Expertise Center registry (Paris, France). The primary outcome was poor neurological outcome defined as Cerebral Performance Category 3, 4, or 5 at hospital discharge. Independent prognostic factors were identified using logistic regression analysis and thresholds defined to stratify low-, moderate-, and high-risk groups. The CAHP score was validated in both a prospective and an external data set (Parisian @entity2 Registry). The developmental data set included 819 @entity0 admitted from May 2011 to December 2012. After multivariate analysis, seven variables were independently associated with poor neurological outcome and subsequently included in the CAHP score (age, non-shockable rhythm, time from collapse to basic life support, time from basic life support to return of spontaneous circulation, location of @entity2 , @entity3 dose, and arterial pH). Three risks groups were identified: low risk (score  <=150, 39% of unfavourable outcome), medium risk (score 150-200, 81% of unfavourable outcome) and high-risk group (score >= 200, 100% of unfavourable outcome). The AUC of the CAHP score were 0.93, and the discrimination value in the validation data sets was consistent (respectively, AUC 0.91 and 0.85). CONCLUSION: The CAHP score represents a simple tool for early stratification of @entity0 admitted in ICU after OHCA. A high-risk category of @entity0 with very poor prognosis can be easily identified.

title: The CAHP ( @entity2 Hospital Prognosis) score: a tool for risk stratification after out-of-hospital XXXX .

answer: @entity2


abstract: BACKGROUND: This report focuses on the adaptive phase I trial design aimed to find the clinically applicable dose for @entity4 maintenance treatment after allogeneic hematopoietic stem cell transplantation in @entity0 with higher-risk @entity2 and secondary @entity3 . METHODS: The first cohort (three @entity0 ) was given the same initial daily dose of @entity4 (5  mg/m(2)/day, five consecutive days with 4-week intervals). In all cohorts, the doses for Cycles 2 to 4 were individualized using pharmacokinetic-pharmacodynamic modeling and simulations. The goal of dose individualization was to determine the maximum dose for each @entity0 at which the occurrence of grade 4 (CTC-AE) @entity1 for both platelet and neutrophil counts could be avoided. The initial doses for the following cohorts were also estimated with the data from the previous cohorts in the same manner. RESULTS: In all but one @entity0 (14 out of 15), neutrophil count was the dose-limiting factor throughout the cycles. In cycles where doses were individualized, the median neutrophil nadir observed was 1100/mm(3) (grade 2) and grade 4 @entity1 occurred in 5.1  % of all cycles (while it occurred in 36.8  % where doses were not individualized). The initial doses estimated for cohorts 2 to 5 were 4, 5, 5.5, and 5  mg/m(2)/day, respectively. The median maintenance dose was 7  mg/m(2)/day. CONCLUSIONS: We determined the acceptable starting dose and individualized the maintenance dose for each @entity0 , while minimizing the @entity1 using the adaptive approach. Currently, 5  mg/m(2)/day is considered to be the most appropriate starting dose for the regimen studied. TRIAL REGISTRATION: Clinicaltrials.gov NCT01277484.

title: Model-based adaptive phase I trial design of post-transplant @entity4 maintenance in XXXX .

answer: @entity2


abstract: BACKGROUND: This report focuses on the adaptive phase I trial design aimed to find the clinically applicable dose for @entity4 maintenance treatment after allogeneic hematopoietic stem cell transplantation in @entity0 with higher-risk @entity2 and secondary @entity3 . METHODS: The first cohort (three @entity0 ) was given the same initial daily dose of @entity4 (5  mg/m(2)/day, five consecutive days with 4-week intervals). In all cohorts, the doses for Cycles 2 to 4 were individualized using pharmacokinetic-pharmacodynamic modeling and simulations. The goal of dose individualization was to determine the maximum dose for each @entity0 at which the occurrence of grade 4 (CTC-AE) @entity1 for both platelet and neutrophil counts could be avoided. The initial doses for the following cohorts were also estimated with the data from the previous cohorts in the same manner. RESULTS: In all but one @entity0 (14 out of 15), neutrophil count was the dose-limiting factor throughout the cycles. In cycles where doses were individualized, the median neutrophil nadir observed was 1100/mm(3) (grade 2) and grade 4 @entity1 occurred in 5.1  % of all cycles (while it occurred in 36.8  % where doses were not individualized). The initial doses estimated for cohorts 2 to 5 were 4, 5, 5.5, and 5  mg/m(2)/day, respectively. The median maintenance dose was 7  mg/m(2)/day. CONCLUSIONS: We determined the acceptable starting dose and individualized the maintenance dose for each @entity0 , while minimizing the @entity1 using the adaptive approach. Currently, 5  mg/m(2)/day is considered to be the most appropriate starting dose for the regimen studied. TRIAL REGISTRATION: Clinicaltrials.gov NCT01277484.

title: Model-based adaptive phase I trial design of post-transplant XXXX maintenance in @entity2 .

answer: @entity4


abstract: @entity6 is a common @entity3 , and many of its symptoms are similar to those of @entity1 . Despite a long discussion on the role of microbiologic agents in @entity1 , @entity6 has never been investigated. We studied @entity6 as assessed by the occurrence of cysts in 86 @entity0 with @entity1 , in 82 @entity0 with other @entity4 , and in 52 @entity0 without @entity4 . In addition, in 20 @entity0 with @entity1 the effects of @entity5 on @entity6 and disease activity were studied. Frequency of @entity6 was 61.6% in @entity0 with @entity1 , 31.7% in @entity0 with other @entity4 , and 5.8% in the control group (p less than 0.01). Stool frequency, disease activity, and humoral signs of @entity2 in @entity0 with @entity1 showed no relationship to @entity6 . All but two @entity0 treated with @entity5 became free of cysts. @entity1 activity index decreased in 14 of 20 @entity0 (p less than 0.05). In conclusion, @entity6 is a common finding in @entity0 with @entity1 . Treatment of @entity6 can, in individual cases of @entity1 , result in a quick recovery from symptoms of high disease activity.

title: XXXX is frequently complicated by @entity6 .

answer: @entity1


abstract: @entity6 is a common @entity3 , and many of its symptoms are similar to those of @entity1 . Despite a long discussion on the role of microbiologic agents in @entity1 , @entity6 has never been investigated. We studied @entity6 as assessed by the occurrence of cysts in 86 @entity0 with @entity1 , in 82 @entity0 with other @entity4 , and in 52 @entity0 without @entity4 . In addition, in 20 @entity0 with @entity1 the effects of @entity5 on @entity6 and disease activity were studied. Frequency of @entity6 was 61.6% in @entity0 with @entity1 , 31.7% in @entity0 with other @entity4 , and 5.8% in the control group (p less than 0.01). Stool frequency, disease activity, and humoral signs of @entity2 in @entity0 with @entity1 showed no relationship to @entity6 . All but two @entity0 treated with @entity5 became free of cysts. @entity1 activity index decreased in 14 of 20 @entity0 (p less than 0.05). In conclusion, @entity6 is a common finding in @entity0 with @entity1 . Treatment of @entity6 can, in individual cases of @entity1 , result in a quick recovery from symptoms of high disease activity.

title: @entity1 is frequently complicated by XXXX .

answer: @entity6


abstract: In the sphere of dialysis treatment, the questions of adequacy of this form of treatment are receiving increasing attention. One of the criteria for the evaluation of this problem is no doubt the functional and anatomical state of the body. As the eye findings form an integral part of the entire clinical picture, the occurrence of pathological @entity1 found after long term dialysis treatment (LTDT) can be used as a criterion of adequacy of the chosen treatment. Eye findings were evaluated in 12 @entity0 with @entity2 treated by haemodialysis for at least 10 years. On the external eye segment, most evident were degenerative changes of the pinguecula type, occurring in all @entity0 . In all cases we also observed a massive disturbance of the retinal electrical activity (REA). In 58% of all examined @entity0 we found a peculiar yellow-brownish pigmentation of the eye background. Greater or smaller alterations in the intra-ocular microcirculation in the chorioideal, retinal and papillary circulation regions were proven fluoroangiographically in all @entity0 . In 5 eyes a marked disturbance of central vision was found as a result of pathological changes of the retinal centres or atrophy of the optic nerve. We may sum up that the haemodialysis treatment is yet not able to maintain all functions of the body at a satisfactory level.

title: XXXX after long-term dialysis treatment.

answer: @entity1


abstract: OBJECTIVE: To estimate the prevalence of musculoskeletal (MSK) disorders and to describe predicting variables associated with @entity4 in 5 regions of M  xico. METHODS: This was a cross-sectional, community-based study performed in 5 regions in M  xico. The methodology followed the guidelines proposed by the Community Oriented Program for the Control of the @entity4 (COPCORD). A standardized methodology was used at all sites, with trained personnel following a common protocol of interviewing adult subjects in their household. A "positive case" was defined as an individual with nontraumatic @entity5 of > 1 on a visual analog @entity0 scale (0 to 10) during the last 7 days. All positive cases were referred to internists or rheumatologists for further clinical evaluation, diagnosis, and proper treatment. RESULTS: The study included 19,213 individuals; 11,602 (68.8%) were female, and their mean age was 42.8 (SD 17.9) years. The prevalence of @entity5 was 25.5%, but significant variations (7.1% to 43.5%) across geographical regions occurred. The prevalence of @entity3 was 10.5%, back @entity0 5.8%, rheumatic regional @entity0 syndromes 3.8%, @entity2 1.6%, @entity1 0.7%, and gout 0.3%. The prevalence of MSK manifestations was associated with older age and female gender. CONCLUSION: The prevalence of @entity5 in our study was 25.5%. Geographic variations in the prevalence of @entity5 and specific diagnoses suggested a role for geographic factors in the prevalence of @entity4 .

title: Epidemiology of the XXXX in Mexico. A study of 5 regions based on the COPCORD methodology.

answer: @entity4


abstract: BACKGROUND: FSH-secreting @entity2 are extremely rare in @entity0 and are seldom associated with clinical manifestations of high serum gonadotrophin levels. Thus, most @entity0 have a late presentation, usually as macroadenomas. CASE REPORTS: Two different clinical forms of presentation of FSH-secreting @entity2 are reported: one in a 12-year-old @entity0 with @entity4 due to a @entity6 , probably FSH-secreting, and the other in a 15-year-old @entity0 with @entity7 due to an FSH-producing macroadenoma. Both @entity0 presented slightly high or high FSH with low LH and high inhibin B levels. In the first case, the microadenoma was treated medically with @entity8 , which failed to reduce FSH and inhibin B levels. No radiological progression has been observed despite increasing testicular volume. In the second case, surgery was performed on the macroadenoma, leading to a decrease in FSH and inhibin B levels. The @entity0 developed severe @entity1 and is currently under treatment with @entity3 . CONCLUSIONS: FSH-secreting @entity2 have an extremely variable clinical expression. The discrepancy between normal or slightly increased FSH and low LH values, together with high inhibin B levels, strongly suggests FSH @entity5 which should be studied.

title: @entity4 and XXXX : two different forms of presentation of FSH-secreting @entity2 in adolescence.

answer: @entity7


abstract: BACKGROUND: FSH-secreting @entity2 are extremely rare in @entity0 and are seldom associated with clinical manifestations of high serum gonadotrophin levels. Thus, most @entity0 have a late presentation, usually as macroadenomas. CASE REPORTS: Two different clinical forms of presentation of FSH-secreting @entity2 are reported: one in a 12-year-old @entity0 with @entity4 due to a @entity6 , probably FSH-secreting, and the other in a 15-year-old @entity0 with @entity7 due to an FSH-producing macroadenoma. Both @entity0 presented slightly high or high FSH with low LH and high inhibin B levels. In the first case, the microadenoma was treated medically with @entity8 , which failed to reduce FSH and inhibin B levels. No radiological progression has been observed despite increasing testicular volume. In the second case, surgery was performed on the macroadenoma, leading to a decrease in FSH and inhibin B levels. The @entity0 developed severe @entity1 and is currently under treatment with @entity3 . CONCLUSIONS: FSH-secreting @entity2 have an extremely variable clinical expression. The discrepancy between normal or slightly increased FSH and low LH values, together with high inhibin B levels, strongly suggests FSH @entity5 which should be studied.

title: XXXX and @entity7 : two different forms of presentation of FSH-secreting @entity2 in adolescence.

answer: @entity4


abstract: BACKGROUND: FSH-secreting @entity2 are extremely rare in @entity0 and are seldom associated with clinical manifestations of high serum gonadotrophin levels. Thus, most @entity0 have a late presentation, usually as macroadenomas. CASE REPORTS: Two different clinical forms of presentation of FSH-secreting @entity2 are reported: one in a 12-year-old @entity0 with @entity4 due to a @entity6 , probably FSH-secreting, and the other in a 15-year-old @entity0 with @entity7 due to an FSH-producing macroadenoma. Both @entity0 presented slightly high or high FSH with low LH and high inhibin B levels. In the first case, the microadenoma was treated medically with @entity8 , which failed to reduce FSH and inhibin B levels. No radiological progression has been observed despite increasing testicular volume. In the second case, surgery was performed on the macroadenoma, leading to a decrease in FSH and inhibin B levels. The @entity0 developed severe @entity1 and is currently under treatment with @entity3 . CONCLUSIONS: FSH-secreting @entity2 have an extremely variable clinical expression. The discrepancy between normal or slightly increased FSH and low LH values, together with high inhibin B levels, strongly suggests FSH @entity5 which should be studied.

title: @entity4 and @entity7 : two different forms of presentation of FSH-secreting XXXX in adolescence.

answer: @entity2


abstract: BACKGROUND: Only a few randomized controlled trials have been carried out to evaluate various complementary treatments for @entity1 . This study assessed the effects of the preseasonal use of @entity3 ( @entity3 ; birch pollen added to honey) or regular honey (RH) on symptoms and medication during birch pollen season. METHODS: Forty-four @entity0 (59% female, mean age 33 years) with physician-diagnosed birch pollen @entity2 consumed either @entity3 or RH daily in incremental amounts from November 2008 to March 2009. Seventeen @entity0 (53% female, mean age 36 years) on their usual @entity2 medication served as the control group. From April to May, @entity0 recorded daily rhinoconjunctival and other symptoms and their use of medication. Fifty @entity0 completed the study. RESULTS: During birch pollen season in 2009, @entity3 @entity0 reported a 60% lower total symptom score (p < 0.01), twice as many asymptomatic days (p < 0.01), and 70% fewer days with severe symptoms (p < 0.001), and they used 50% less antihistamines (p < 0.001) compared to the control group. The differences between the @entity3 and RH groups were not significant. However, the @entity3 @entity0 used less antihistamines than did the RH @entity0 (p < 0.05). CONCLUSIONS: @entity0 who preseasonally used @entity3 had significantly better control of their symptoms than did those on conventional medication only, and they had marginally better control compared to those on RH. The results should be regarded as preliminary, but they indicate that @entity3 could serve as a complementary therapy for birch pollen @entity2 .

title: Birch pollen honey for birch pollen XXXX --a randomized controlled pilot study.

answer: @entity2


abstract: OBJECTIVES: To improve the existing animal models ( @entity0 , @entity1 , and hamsters) for radiotherapy-induced @entity4 (RTOM), thereby establishing a radiotherapy-induced @entity7 (RTG) Sprague-Dawley (SD) @entity1 model. STUDY DESIGN: A lead device was designed to limit radiation exposure to a 1x1 cm2 area of a @entity1 's dorsal anterior tongue with a single 30 Gy of X-ray radiation. The general conditions of the irradiated @entity1 , such as body-weight and behavior, were observed. The @entity4 index (OMI) of the RTG @entity1 were measured daily. Histological changes of the irradiated tongue tissues were assayed by H _E staining. RESULTS AND CONCLUSION: No significant changes were clinically observed 3 to 4 days after irradiation. At 5 to 6 day, punctuation and confluenced @entity5 were observed. The small blood vessels became more extensive, engorged, thin vessel walls. More infiltrating cells were observable, @entity2 and exfoliation of the squamous cells appeared, and the formation of an @entity3 could be observed. Seven to 15 days, the exfoliated epithelial layer was observed to have formed an @entity3 , then aggravated @entity3 consisting of @entity6 exudates could be observed. The structure of the epithelium had become completely disintegrated, forming deep, microscopic @entity3 . Twenty-one days, the periphery of the @entity3 was observed to have begun to heal, and granulation tissue could be observed at the bottom of the @entity3 . At 35 days after irradiation, the epithelial structure presented again, but the epithelium was very thin. An RTG animal model was successfully established in SD @entity1 , which provides a new research platform for the study of RTOM pathogenesis.

title: The development and inflammatory features of radiotherapy-induced XXXX in @entity1 .

answer: @entity7


abstract: OBJECTIVES: To improve the existing animal models ( @entity0 , @entity1 , and hamsters) for radiotherapy-induced @entity4 (RTOM), thereby establishing a radiotherapy-induced @entity7 (RTG) Sprague-Dawley (SD) @entity1 model. STUDY DESIGN: A lead device was designed to limit radiation exposure to a 1x1 cm2 area of a @entity1 's dorsal anterior tongue with a single 30 Gy of X-ray radiation. The general conditions of the irradiated @entity1 , such as body-weight and behavior, were observed. The @entity4 index (OMI) of the RTG @entity1 were measured daily. Histological changes of the irradiated tongue tissues were assayed by H _E staining. RESULTS AND CONCLUSION: No significant changes were clinically observed 3 to 4 days after irradiation. At 5 to 6 day, punctuation and confluenced @entity5 were observed. The small blood vessels became more extensive, engorged, thin vessel walls. More infiltrating cells were observable, @entity2 and exfoliation of the squamous cells appeared, and the formation of an @entity3 could be observed. Seven to 15 days, the exfoliated epithelial layer was observed to have formed an @entity3 , then aggravated @entity3 consisting of @entity6 exudates could be observed. The structure of the epithelium had become completely disintegrated, forming deep, microscopic @entity3 . Twenty-one days, the periphery of the @entity3 was observed to have begun to heal, and granulation tissue could be observed at the bottom of the @entity3 . At 35 days after irradiation, the epithelial structure presented again, but the epithelium was very thin. An RTG animal model was successfully established in SD @entity1 , which provides a new research platform for the study of RTOM pathogenesis.

title: The development and inflammatory features of radiotherapy-induced @entity7 in XXXX .

answer: @entity1


abstract: Total nutrient admixture (TNA) combines @entity4 , lipids, and @entity2 in a single bottle for continuous parenteral use. This cost-effective and easily administered solution is now available for use in neonates. The present study was performed to assess the metabolism of fat administered as TNA in sick neonates as reflected by serum free @entity3 (FFA) and @entity1 (TG) levels. During a 6-month period, TG and FFA levels were monitored in all @entity0 receiving TNA. Levels were measured within 24 hours of a change in lipid dose and then weekly when maximum intake (about 2 g/kg/day) was achieved. Sixty-nine TG and 58 FFA levels were obtained from 42 neonates who at the time of sampling were receiving 2 g/kg/day or more of parenteral lipid. Ninety-one percent of TG levels were less than or equal to 200 mg/dL. Ninety-six percent of @entity5 levels were less than or equal to 2000 mumol/L. A weak but statistically significant correlation was noted between TG and FFA levels with a correlation coefficient of 0.54. In conclusion, although the range of FFA and TG levels obtained from sick neonates on TNA therapy is relatively wide, these levels are comparable to those reported in the literature for @entity0 receiving standard intravenous lipid infusions.

title: Free @entity3 and XXXX levels in neonates receiving triple mix hyperalimentation.

answer: @entity1


abstract: Total nutrient admixture (TNA) combines @entity4 , lipids, and @entity2 in a single bottle for continuous parenteral use. This cost-effective and easily administered solution is now available for use in neonates. The present study was performed to assess the metabolism of fat administered as TNA in sick neonates as reflected by serum free @entity3 (FFA) and @entity1 (TG) levels. During a 6-month period, TG and FFA levels were monitored in all @entity0 receiving TNA. Levels were measured within 24 hours of a change in lipid dose and then weekly when maximum intake (about 2 g/kg/day) was achieved. Sixty-nine TG and 58 FFA levels were obtained from 42 neonates who at the time of sampling were receiving 2 g/kg/day or more of parenteral lipid. Ninety-one percent of TG levels were less than or equal to 200 mg/dL. Ninety-six percent of @entity5 levels were less than or equal to 2000 mumol/L. A weak but statistically significant correlation was noted between TG and FFA levels with a correlation coefficient of 0.54. In conclusion, although the range of FFA and TG levels obtained from sick neonates on TNA therapy is relatively wide, these levels are comparable to those reported in the literature for @entity0 receiving standard intravenous lipid infusions.

title: Free XXXX and @entity1 levels in neonates receiving triple mix hyperalimentation.

answer: @entity3


abstract: INTRODUCTION: @entity1 is a worldwide problem and has grown in severity in the last few decades making bariatric surgery and, in particular, laparoscopic banding and Roux-en-Y gastric bypass efficacious and cost-effective procedures. The laparoscopic approach has been shown to offer significant healthcare benefits, of particular interests are reports of @entity3 resulting in a shorter hospital stay and an earlier return to normal activity. However, many @entity0 still experience significant @entity2 , including shoulder @entity2 , that require strong analgesia including opiates during their early recovery period. The aims of this study were to establish the safe use of the aerosolization technique in bariatric surgery and to investigate the possible benefits in reducing @entity3 . METHODS: In this study, fifty @entity0 undergoing laparoscopic gastric bypass were recruited and divided into two groups; control (n = 25) and therapeutic (n = 25). The control group received intraperitoneal aerosolization of 10 mL of 0.9% normal saline while the therapeutic group received 10 mL of 0.5% @entity4 . All the @entity0 had standard preoperative, intraoperative, and postoperative care. @entity2 scores were carried out by the nursing staff in recovery and 6 h, 12 h and 24 h postoperatively using a standard 0-10 @entity2 scoring scale. In addition, opiate consumption via @entity0 -controlled analgesia (PCA) was recorded. RESULTS: Aerosolized @entity4 reduced @entity3 in comparison to normal saline (p < 0.05). However, PCA usage showed no statistically significant change from the control group. CONCLUSION: The aims of this study were achieved and we were able to establish the safe use of the aerosolization technique in bariatric surgery and its benefits in reducing @entity3 .

title: Intraperitoneal aerosolization of @entity4 is a safe and effective method in controlling XXXX in laparoscopic Roux-en-Y gastric bypass.

answer: @entity3


abstract: INTRODUCTION: @entity1 is a worldwide problem and has grown in severity in the last few decades making bariatric surgery and, in particular, laparoscopic banding and Roux-en-Y gastric bypass efficacious and cost-effective procedures. The laparoscopic approach has been shown to offer significant healthcare benefits, of particular interests are reports of @entity3 resulting in a shorter hospital stay and an earlier return to normal activity. However, many @entity0 still experience significant @entity2 , including shoulder @entity2 , that require strong analgesia including opiates during their early recovery period. The aims of this study were to establish the safe use of the aerosolization technique in bariatric surgery and to investigate the possible benefits in reducing @entity3 . METHODS: In this study, fifty @entity0 undergoing laparoscopic gastric bypass were recruited and divided into two groups; control (n = 25) and therapeutic (n = 25). The control group received intraperitoneal aerosolization of 10 mL of 0.9% normal saline while the therapeutic group received 10 mL of 0.5% @entity4 . All the @entity0 had standard preoperative, intraoperative, and postoperative care. @entity2 scores were carried out by the nursing staff in recovery and 6 h, 12 h and 24 h postoperatively using a standard 0-10 @entity2 scoring scale. In addition, opiate consumption via @entity0 -controlled analgesia (PCA) was recorded. RESULTS: Aerosolized @entity4 reduced @entity3 in comparison to normal saline (p < 0.05). However, PCA usage showed no statistically significant change from the control group. CONCLUSION: The aims of this study were achieved and we were able to establish the safe use of the aerosolization technique in bariatric surgery and its benefits in reducing @entity3 .

title: Intraperitoneal aerosolization of XXXX is a safe and effective method in controlling @entity3 in laparoscopic Roux-en-Y gastric bypass.

answer: @entity4


abstract: The protective effects of Asparagus racemosus (AR) and Tinospora cordifolia (TC) against myelosuppression induced by single doses of @entity2 (CP) have been previously reported. Presented here are the results of a comparative study between AR, TC, glucan and @entity5 against the myelosuppressive effects of single and multiple doses of @entity2 in @entity1 . @entity2 was administered as a single dose 200 mg/kg subcutaneously to one group of @entity1 , while a second group received 3 doses of 30 mg/kg intraperitoneally. Both groups received AR, TC and @entity3 orally for 15 days before CP. Glucan was administered intravenously in 3 doses, before @entity2 in the first group and together with @entity2 in the second group. In both groups peripheral and differential WBC counts were done before and after drug treatment and serially after @entity2 injection. All four drugs produced leucocytosis with @entity6 . When compared to control group, all 4 drugs prevented, to varying degrees, @entity4 produced by @entity2 . We conclude, therefore, that both indigenous plants, AR and TC, are potent immunostimulants, with effects comparable to @entity3 and glucan. They need further evaluation in @entity0 receiving cytotoxic drugs.

title: Comparative study of immunomodulating activity of Indian medicinal plants, XXXX and glucan.

answer: @entity5


abstract: OBJECTIVE: The aim was to gain knowledge of @entity2 ( @entity2 ) @entity0 on long-term sick leave and with particular difficulties in resuming work, and to compare them with @entity0 with @entity4 , back or joint diagnoses, and @entity3 . METHODS: @entity0 were identified by and referred from social insurance offices and were multidisciplinarily examined by three board-certified specialists in psychiatry, orthopedic surgery and rehabilitation medicine. Ninety-two @entity0 were diagnosed with @entity2 only. Three female comparison groups were chosen: @entity3 , back/joint diagnoses, and @entity4 . RESULTS AND CONCLUSIONS: Ceaseless @entity1 was reported by 73% of @entity2 @entity0 , 54% of back/joint diagnoses @entity0 , 43% of @entity4 @entity0 , and 35% of @entity3 @entity0 . The distribution of @entity1 (>50%) in @entity2 @entity0 was to almost all regions of the body, and in @entity3 @entity0 to the lower dorsal neck, upper shoulders and lumbosacral back but not in the anterior body. Reduced sleep was more evident in @entity2 @entity0 . @entity2 @entity0 did not meet more criteria for @entity5 than @entity0 with the other @entity1 conditions. The most common dimension of "personality traits" of @entity1 conditions was the "obsessive compulsive" but at a level clearly below that indicating a @entity5 . More @entity2 @entity0 experienced disabilities, the most common being in the mobility and domestic-life areas.

title: Long-term sick-leavers with @entity2 : Comparing their multidisciplinarily assessed characteristics with those of others with chronic pain conditions and XXXX .

answer: @entity3


abstract: OBJECTIVE: The aim was to gain knowledge of @entity2 ( @entity2 ) @entity0 on long-term sick leave and with particular difficulties in resuming work, and to compare them with @entity0 with @entity4 , back or joint diagnoses, and @entity3 . METHODS: @entity0 were identified by and referred from social insurance offices and were multidisciplinarily examined by three board-certified specialists in psychiatry, orthopedic surgery and rehabilitation medicine. Ninety-two @entity0 were diagnosed with @entity2 only. Three female comparison groups were chosen: @entity3 , back/joint diagnoses, and @entity4 . RESULTS AND CONCLUSIONS: Ceaseless @entity1 was reported by 73% of @entity2 @entity0 , 54% of back/joint diagnoses @entity0 , 43% of @entity4 @entity0 , and 35% of @entity3 @entity0 . The distribution of @entity1 (>50%) in @entity2 @entity0 was to almost all regions of the body, and in @entity3 @entity0 to the lower dorsal neck, upper shoulders and lumbosacral back but not in the anterior body. Reduced sleep was more evident in @entity2 @entity0 . @entity2 @entity0 did not meet more criteria for @entity5 than @entity0 with the other @entity1 conditions. The most common dimension of "personality traits" of @entity1 conditions was the "obsessive compulsive" but at a level clearly below that indicating a @entity5 . More @entity2 @entity0 experienced disabilities, the most common being in the mobility and domestic-life areas.

title: Long-term sick-leavers with XXXX : Comparing their multidisciplinarily assessed characteristics with those of others with chronic pain conditions and @entity3 .

answer: @entity2


abstract: Regional variations in the size and shape of isolated myocytes were studied using the two-kidney, one clip (2K1C) renal model of @entity1 . Weanling male @entity0 (50 to 75 g) were anesthetized by @entity6 (100 mg/kg) during renal artery clipping (0.2 mm internal diameter @entity3 clip) and were then allowed to grow for 6 to 8 weeks, when the blood pressure had stabilized at 180 mmHg. Hearts were removed, weighed and then were perfused with a @entity2 -free Joklik medium containing collagenase. Isolated myocytes were collected from five regions and fixed in isoosmolar @entity5 : right ventricular free wall (RVFW), right and left halves of the interventricular septum (RIVS, LIVS), and epicardial and endocardial halves of the left ventricular free wall (LEPI, LENDO). Myocyte volume was measured by Coulter Counter. Myocyte length was measured by sonic digitizer. Cross-sectional area was calculated from myocyte volume and length. Tailcuff systolic pressure and heart weight were significantly increased in 2K1C @entity0 as compared to control. Body weights were not different. Cell volume was significantly increased in RIVS, LIVS, LEPI, and LENDO, but not in RVFW. Cell length was not significantly increased in any region. Thus, the 2K1C model showed a predominant @entity7 in which the right half of the septum acted in concert with the left ventricle. The shape of the hypertrophied myocytes, having an increase in volume due to an increase in cross-sectional area but not length, was most consistent with a pressure-induced form of @entity4 .

title: Regional myocyte size in two-kidney, one clip renal XXXX .

answer: @entity1


abstract: UNASSIGNED: Hirsutella sinensis mycelium (HSM), the anamorph of Cordyceps sinensis, is a traditional Chinese medicine that has been shown to possess various pharmacological properties. We previously reported that this fungus suppresses @entity7 and @entity12 secretion by inhibiting both canonical and non-canonical inflammasomes in @entity0 macrophages. However, whether HSM may be used to prevent @entity4 and the mechanism underlying this activity remain unclear. Our results show that pretreatment with HSM inhibits @entity10 -induced expression of fibronectin and @entity9 in lung fibroblasts. HSM also restores @entity5 dismutase expression in @entity10 -treated lung fibroblasts and inhibits reactive @entity2 species production in lung epithelial cells. Furthermore, HSM pretreatment markedly reduces @entity8 -induced @entity6 and @entity4 in @entity1 . Accordingly, HSM reduces inflammatory cell accumulation in bronchoalveolar lavage fluid and proinflammatory cytokines levels in lung tissues. The HSM extract also significantly reduces @entity10 in lung tissues, and this effect is accompanied by decreased collagen 3a1 and @entity9 levels. Moreover, HSM reduces expression of the @entity11 inflammasome and P2X7R in lung tissues, whereas it enhances expression of @entity5 dismutase. These findings suggest that HSM may be used for the treatment of @entity3 and @entity4 .

title: Hirsutella sinensis mycelium attenuates @entity8 -induced @entity3 and XXXX in vivo.

answer: @entity4


abstract: UNASSIGNED: Hirsutella sinensis mycelium (HSM), the anamorph of Cordyceps sinensis, is a traditional Chinese medicine that has been shown to possess various pharmacological properties. We previously reported that this fungus suppresses @entity7 and @entity12 secretion by inhibiting both canonical and non-canonical inflammasomes in @entity0 macrophages. However, whether HSM may be used to prevent @entity4 and the mechanism underlying this activity remain unclear. Our results show that pretreatment with HSM inhibits @entity10 -induced expression of fibronectin and @entity9 in lung fibroblasts. HSM also restores @entity5 dismutase expression in @entity10 -treated lung fibroblasts and inhibits reactive @entity2 species production in lung epithelial cells. Furthermore, HSM pretreatment markedly reduces @entity8 -induced @entity6 and @entity4 in @entity1 . Accordingly, HSM reduces inflammatory cell accumulation in bronchoalveolar lavage fluid and proinflammatory cytokines levels in lung tissues. The HSM extract also significantly reduces @entity10 in lung tissues, and this effect is accompanied by decreased collagen 3a1 and @entity9 levels. Moreover, HSM reduces expression of the @entity11 inflammasome and P2X7R in lung tissues, whereas it enhances expression of @entity5 dismutase. These findings suggest that HSM may be used for the treatment of @entity3 and @entity4 .

title: Hirsutella sinensis mycelium attenuates @entity8 -induced XXXX and @entity4 in vivo.

answer: @entity3


abstract: UNASSIGNED: Hirsutella sinensis mycelium (HSM), the anamorph of Cordyceps sinensis, is a traditional Chinese medicine that has been shown to possess various pharmacological properties. We previously reported that this fungus suppresses @entity7 and @entity12 secretion by inhibiting both canonical and non-canonical inflammasomes in @entity0 macrophages. However, whether HSM may be used to prevent @entity4 and the mechanism underlying this activity remain unclear. Our results show that pretreatment with HSM inhibits @entity10 -induced expression of fibronectin and @entity9 in lung fibroblasts. HSM also restores @entity5 dismutase expression in @entity10 -treated lung fibroblasts and inhibits reactive @entity2 species production in lung epithelial cells. Furthermore, HSM pretreatment markedly reduces @entity8 -induced @entity6 and @entity4 in @entity1 . Accordingly, HSM reduces inflammatory cell accumulation in bronchoalveolar lavage fluid and proinflammatory cytokines levels in lung tissues. The HSM extract also significantly reduces @entity10 in lung tissues, and this effect is accompanied by decreased collagen 3a1 and @entity9 levels. Moreover, HSM reduces expression of the @entity11 inflammasome and P2X7R in lung tissues, whereas it enhances expression of @entity5 dismutase. These findings suggest that HSM may be used for the treatment of @entity3 and @entity4 .

title: Hirsutella sinensis mycelium attenuates XXXX -induced @entity3 and @entity4 in vivo.

answer: @entity8


abstract: BACKGROUND: @entity4 is a seldom encountered disease of the breast. Based on the results of previous studies and our own experience, we investigated the clinical characteristics of @entity0 . METHOD: Four @entity1 who were treated for @entity0 at Samsung Medical Center were included in the study, and additional data were retrieved from the Index Medicus and the Science Citation Index (SCI). The Korean Medical (KM) database and the Korean Association of Medical Journal Editors (KAMJE) database were searched to include information from Korean journals that is not included in international citation indexes. RESULTS: Among 35 @entity1 , 8 (32%) had a record of oral ingestion of an intermediary host. All @entity1 presented with a breast mass, with migration in 6 cases (25%) and @entity3 or an itching sensation in 6 cases (25%). Elongated tubular structures were found in the subcutaneous layer in 22 cases (88%) during radiologic exam. All @entity1 underwent complete surgical excision. Twenty-seven of 29 (93.1%) @entity1 ' spargana was separated and confirmed grossly. Histologically, @entity2 was the most common feature. A single worm was extracted in 16 cases (76.2%) and 5 cases (23.8%) had multiple worms. CONCLUSION: @entity4 tends to present as a suspicious mass in the subcutaneous layer of the breast. Complete surgical excision is the treatment of choice, with careful postoperative surveillance.

title: Cases and literature review of XXXX .

answer: @entity0


abstract: 1. Pressor responses to @entity5 ( @entity2 ) were determined in the @entity0 isolated superior mesenteric arterial bed perfused with Krebs-Henseleit solution and compared with those to @entity1 . 2. In control preparations the maximum pressor response to the peptide was 34 +/- 3 mmHg and the ED50 was 21 +/- 4 mu (n = 11). The maximal pressor response to @entity1 (30 micrograms) was 100 +/- 6 mmHg (n = 8). After removal of the functional endothelium with the detergent CHAPS, the maximum pressor response to AVP increased to 64 +/- 4 mmHg and the ED50 decreased to 7.7 +/- 2.0 mu (n = 11) but the response to 10 micrograms @entity1 was unaffected. 3. @entity3 (2.5 microM) significantly increased the maximum pressor response to AVP from 41 +/- 2 mmHg to 86 +/- 8 mmHg (n = 9); the ED50 was unchanged. @entity6 (50 microM) also increased the maximum response from 41 +/- 3 mmHg to 87 +/- 13 mmHg (n = 8) without affecting the ED50. Neither treatment significantly affected the response to 10 micrograms @entity1 . 4. Neither @entity4 (10 microM) nor BW755C (10 microM) had significant effects upon either the maximal response or ED50 for AVP nor did they affect the response to 10 micrograms @entity1 . 5. In 6 preparations SKF-525A significantly increased both the ED50, from 9.8 +/- 2.1 to 22 +/- 2 mu, and the maximum response, from 36 +/- 2 to 70 +/- 3 mmHg. 6. It is concluded that the pressor response to AVP in this vascular bed is modulated, in the presence of functional endothelium, by the simultaneous release of endothelium-derived relaxing factor.

title: Endothelium-dependent modulation of the pressor activity of XXXX in the isolated superior mesenteric arterial bed of the @entity0 .

answer: @entity5


abstract: 1. Pressor responses to @entity5 ( @entity2 ) were determined in the @entity0 isolated superior mesenteric arterial bed perfused with Krebs-Henseleit solution and compared with those to @entity1 . 2. In control preparations the maximum pressor response to the peptide was 34 +/- 3 mmHg and the ED50 was 21 +/- 4 mu (n = 11). The maximal pressor response to @entity1 (30 micrograms) was 100 +/- 6 mmHg (n = 8). After removal of the functional endothelium with the detergent CHAPS, the maximum pressor response to AVP increased to 64 +/- 4 mmHg and the ED50 decreased to 7.7 +/- 2.0 mu (n = 11) but the response to 10 micrograms @entity1 was unaffected. 3. @entity3 (2.5 microM) significantly increased the maximum pressor response to AVP from 41 +/- 2 mmHg to 86 +/- 8 mmHg (n = 9); the ED50 was unchanged. @entity6 (50 microM) also increased the maximum response from 41 +/- 3 mmHg to 87 +/- 13 mmHg (n = 8) without affecting the ED50. Neither treatment significantly affected the response to 10 micrograms @entity1 . 4. Neither @entity4 (10 microM) nor BW755C (10 microM) had significant effects upon either the maximal response or ED50 for AVP nor did they affect the response to 10 micrograms @entity1 . 5. In 6 preparations SKF-525A significantly increased both the ED50, from 9.8 +/- 2.1 to 22 +/- 2 mu, and the maximum response, from 36 +/- 2 to 70 +/- 3 mmHg. 6. It is concluded that the pressor response to AVP in this vascular bed is modulated, in the presence of functional endothelium, by the simultaneous release of endothelium-derived relaxing factor.

title: Endothelium-dependent modulation of the pressor activity of @entity5 in the isolated superior mesenteric arterial bed of the XXXX .

answer: @entity0